Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

被引:149
作者
Brodie, SG [1 ]
Xu, XL [1 ]
Qiao, WH [1 ]
Li, WM [1 ]
Cao, L [1 ]
Deng, CX [1 ]
机构
[1] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA
关键词
Brca1; p53; ErbB2; cyclin D1; c-Myc; tumorigenesis;
D O I
10.1038/sj.onc.1204929
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Germline mutations in the tumor suppressor gene BRCA1 predispose women to breast cancer, however somatic mutations in the gene are rarely detected in sporadic cancers. To understand this phenomenon, we examined mouse models carrying conditional disruption of Brca1 in mammary epithelium in either p53 wild type (wt) or heterozygous backgrounds. Although a p53(+/-) mutation significantly accelerated tumorigenesis, both strains developed mammary tumors in a stochastic fashion, suggesting that multiple factors, in addition to p53 mutations, may be involved in Brca1 related tumorigenesis. A unique feature of Brca1 mammary tumors is their highly diverse histopathology accompanied by severe chromosome abnormalities. The tumors also display extensive genetic/molecular alterations, including overexpression of ErbB2, c-Myc, p27 and Cyclin D1 in the majority of tumors, while they were virtually ER alpha and p16 negative. Translocations involving p53 were also identified which lead to abnormal RNA and protein products. In addition, we generated cell lines from mammary tumors and found that the cells retained many of the genetic changes found in the primary tumors, suggesting that these genes may be players in Brca1-associated tumorigenesis. Despite their distinct morphology, all cultured tumor cells were Tamoxifen resistant but highly sensitive to Doxorubicin or irradiation, suggesting that these methods would be effective in treatment of this disease.
引用
收藏
页码:7514 / 7523
页数:10
相关论文
共 71 条
  • [1] Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003
  • [2] BRCA1-associated growth arrest is RB-dependent
    Aprelikova, ON
    Fang, BS
    Meissner, EG
    Cotter, S
    Campbell, M
    Kuthiala, A
    Bessho, M
    Jensen, RA
    Liu, ET
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) : 11866 - 11871
  • [3] Barbareschi M, 2000, INT J CANCER, V89, P236, DOI 10.1002/1097-0215(20000520)89:3<236::AID-IJC5>3.3.CO
  • [4] 2-Q
  • [5] Cyclin D1 in breast cancer
    Barnes, DM
    Gillett, CE
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 1 - 15
  • [6] Bièche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO
  • [7] 2-2
  • [8] GENETIC ALTERATIONS IN BREAST-CANCER
    BIECHE, I
    LIDEREAU, R
    [J]. GENES CHROMOSOMES & CANCER, 1995, 14 (04) : 227 - 251
  • [9] Bonsing BA, 2000, GENE CHROMOSOME CANC, V28, P173, DOI 10.1002/(SICI)1098-2264(200006)28:2<173::AID-GCC6>3.0.CO
  • [10] 2-1